Data / Drug companies / Kesin Pharma Corporation
Kesin Pharma Corporation: 61 products in the FDA NDC directory, labeler code 81033
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Kesin Pharma Corporation (labeler code 81033) lists 61 products in the FDA National Drug Code Directory, covering 45 finished drugs by generic name. By type: 43 prescription drugs, 18 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 27, 2026.
The request: Watch Kesin Pharma Corporation (FDA labeler code 81033): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 81033
- Products in commercial distribution
- 61
- Packages
- 93
- Finished drugs by generic name
- 45
- Prescription products
- 43
- Over the counter products
- 18
- Controlled substance products
- Schedule IV 2, Schedule V 2
- Flagged as original packager
- 22 of 22 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- September 21, 1976
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 41 | 67.2% |
| Over the counter monograph drugs | 14 | 23% |
| Other unapproved drugs | 4 | 6.6% |
| Authorized generics (NDA) | 1 | 1.6% |
| New drug applications (NDA) | 1 | 1.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 43 | 70.5% |
| Over the counter drugs | 18 | 29.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 21 | 34.4% |
| Suspension | 14 | 23% |
| Tablet, film coated | 8 | 13.1% |
| Tablet | 5 | 8.2% |
| Liquid | 5 | 8.2% |
| Powder, for solution | 2 | 3.3% |
| Ointment | 2 | 3.3% |
| Syrup | 1 | 1.6% |
| Powder, for suspension | 1 | 1.6% |
| Elixir | 1 | 1.6% |
| Granule, for solution | 1 | 1.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| CHILDRENS Acetaminophen | 81033-026 | Suspension | Over the counter monograph drugs | February 27, 2026 |
| Atovaquone Oral Suspension | 81033-105 | Suspension | Generic drugs (ANDA) | February 6, 2026 |
| Moxifloxacin | 81033-068 | Tablet, film coated | Generic drugs (ANDA) | December 12, 2025 |
| Phenobarbital Oral Solution | 81033-164 | Solution | Other unapproved drugs | November 5, 2025 |
| Kesin MAG-AL Plus XS | 81033-007 | Suspension | Over the counter monograph drugs | November 5, 2025 |
| Kesin MAG-AL Plus | 81033-006 | Suspension | Over the counter monograph drugs | November 5, 2025 |
| Kesin MAG-AL | 81033-005 | Suspension | Over the counter monograph drugs | November 5, 2025 |
| Megestrol Acetate | 81033-150 | Suspension | Generic drugs (ANDA) | August 7, 2025 |
| Gabapentin | 81033-124 | Solution | Generic drugs (ANDA) | August 6, 2025 |
| Gabapentin | 81033-123 | Solution | Generic drugs (ANDA) | August 6, 2025 |
| Gabapentin | 81033-123 | Solution | Generic drugs (ANDA) | August 6, 2025 |
| Lacosamide Oral Solution | 81033-427 | Solution | Generic drugs (ANDA) | August 5, 2025 |
| Hydroxyzine Hydrochloride | 81033-031 | Solution | Generic drugs (ANDA) | July 17, 2025 |
| Lacosamide Oral Solution | 81033-428 | Solution | Generic drugs (ANDA) | July 14, 2025 |
| Topiramate | 81033-035 | Solution | Generic drugs (ANDA) | July 7, 2025 |
| Polyethylene Glycol 3350 | 81033-762 | Powder, for solution | Generic drugs (ANDA) | June 9, 2025 |
| Mupirocin | 81033-032 | Ointment | Generic drugs (ANDA) | May 28, 2025 |
| Senna Syrup | 81033-120 | Syrup | Over the counter monograph drugs | May 26, 2025 |
| Magnesium Oxide | 81033-027 | Tablet | Over the counter monograph drugs | April 7, 2025 |
| Guaifenesin | 81033-102 | Liquid | Over the counter monograph drugs | April 1, 2025 |
| Docusate Sodium Oral Liquid | 81033-022 | Liquid | Over the counter monograph drugs | April 1, 2025 |
| Sodium Citrate and Citric Acid | 81033-017 | Solution | Other unapproved drugs | April 1, 2025 |
| Diphenhydramine HCl Oral Solution | 81033-029 | Solution | Over the counter monograph drugs | March 4, 2025 |
| Mineral Oil | 81033-042 | Solution | Over the counter monograph drugs | March 1, 2025 |
| Sodium Chloride | 81033-028 | Tablet | Other unapproved drugs | March 1, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.